Paris Cedex 13

• A Phase 2 Master Protocol to assess the efficacy and safety of FORE8394, an inhibitor of BRAF Class 1 and Class 2 alterations, in participan … Recruiting
  2024-513578-23-00 4 2023-03-21 Tumors harboring BRAF alterations
• Randomized prospective trial evaluating the efficacy of the antiCD38 monoclonal antibody isatuximab in the treatment of PCRA by major ABO mi … Recruiting
  2024-514351-14-00 4 2023-02-20 Pure cell red aplasia by major ABO mismatch after allogeneic hematopoi
• Chemotherapy for the treatment of standard risk adult medulloblastomas Recruiting
  2024-513243-85-00 4 2023-02-03 Adult medulloblastoma
• Early discontinuation of steroid treatment in negative FDG-PET/CT patients with idiopathic retroperitoneal fibrosis Recruiting
  2024-514353-30-00 6 2022-11-25 Idiopathic retroperitoneal fibrosis
• TERTIO : Evaluation de l’intérêt de combiner un vaccin inducteur de CD4-Th1 dérivé de la télomérase avec un traitement par atezolizumab et b … Recruiting
  2022-500643-20-00 4 2022-09-27 Patients with locally advanced, metastatic or unresectable hepatocellu
• Combination lock01 - Impact of aminoglycosides-based antibiotics combination and protective isolation on outcomes in critically-ill neutrope … Recruiting
  2024-514042-36-00 5 2022-09-21 Adult patients admitted to intensive care
• DFIL2-REP - Study of the clinical and biological response to repeated administration of low-dose interleukin-2 in patients with type 1 diabe … Recruiting
  2024-514043-29-00 4 2022-09-21 Patient with newly diagnosed (≤ 3 months) type 1 diabetes stage 3
• ASPIC - Antimicrobial Stewardship for Ventilator Associated Pneumonia in Intensive Care Recruiting
  2024-513327-16-00 5 2022-09-20 Intensive care
• CPX-351 versus intensive chemotherapy in patients with de novo intermediate or adverse risk AML stratified by genomics Recruiting
  2022-500295-60-00 4 2022-09-15 Acute Myeloid Leukemia
• Baricitinib in patients with relapsing or naïve dermatomyositis (BIRD) Recruiting
  2024-511899-32-00 10 2022-08-31 Dermatomyositis; Baricitinib in patients with relapsing or naïve derma
• A Phase 3 Study Comparing Pirtobrutinib to Ibrutinib in CLL/SLL Recruiting
  2023-507699-38-00 5 2022-08-30 Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
• Intravenous Immunoglobulins for Prevention of BKV Viremia in Kidney Transplant Recipients According to BKV genotype-specific Neutralizing An … Recruiting
  2024-515243-37-00 11 2022-08-21 Kidney Transplantation BKV infection
• A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-C … Recruiting
  2022-502646-27-00 10 2022-06-24 Relapsed or Refractory Diffuse Large B-Cell Lymphoma
• Fecal Microbiota Transplantation in the prevention of complications after allogeneic hematopoietic stem cell transplantation for hematologic … Recruiting
  2024-512969-14-01 4 2022-05-02 Patient who underwent Allogeneic hematopoietic stem cell transplantati
• Safety, Tolerability, Pharmacodynamic, Efficacy, and Pharmacokinetic Study of DYNE-101 in Participants with Myotonic Dystrophy Type 1 Recruiting
  2023-510353-42-00 7 2022-02-21 Myotonic Dystrophy Type 1
• STUDY TO ASSESS THE SCHEMAS OF RETREATMENT WITH LUTATHERA® IN PATIENTS WITH NEW PROGRESSION OF INTESTINAL WELL-DIFFERENTIATED NEUROENDOCRINE … Recruiting
  2024-511001-28-00 4 2021-12-13 Neuroendocrine tumor
• Efficacy and Safety Study of Nipocalimab IV Infusions for Adults With Generalized Myasthenia Gravis Recruiting
  2023-504152-97-00 5 2021-11-26 Generalized Myasthenia Gravis
• TRIBECA - Multicenter randomized double-blind study comparing the efficacy and safety of belimumab in the treatment of non-infectious active … Recruiting
  2024-516237-12-00 4 2021-10-20 Cryoglobulinemia vasculitis
• IFM2020-05-BENEFIT-Multicenter Open label Phase 3 study of Isatuximab plus Lenalidomide and Dexamethasone with/without Bortezomib in the Tre … Recruiting
  2024-517215-67-00 5 2021-06-11 Newly diagnosed Non-Frail transplant Ineligible Multiple Myeloma elder
• Isatuximab in combination with novel agents in RRMM – Master protocol and control arm Recruiting
  2024-514988-25-00 9 2021-03-31 Cancer
• Isatuximab in combination with SAR445761 (belumosudil) and dexamethasone in relapsed or refractory multiple myeloma Recruiting
  2024-514992-16-00 9 2021-03-31 Cancer
• Isatuximab in combination with evorpacept and dexamethasone in RRMM Recruiting
  2024-514993-38-00 9 2021-03-31 Cancer
• Open-label Phase 2 of tabelecleucel in Subjects with Epstein Barr Virus associated Diseases (EBVision) Recruiting
  2024-516623-14-00 4 2021-03-17 EBV+ primary imunodeficiency lymphoproliferative disease (LPD)
• A multicenter, prospective, randomized, placebo-controlled, double-blind, multi-arm, multi-stage clinical trial of Ivabradine for heart Rate … Recruiting
  2024-515019-22-00 5 2021-02-26 Septic shock

Showing 145–168 of 312 trials